Postar
Happy_shanky
🚨 $LLY — ELI LILLY’S NEXT OBESITY DRUG SHOWS STRONG RESULTS
ELI LILLY’S EXPERIMENTAL ELORALINTIDE, WHEN COMBINED WITH ZEPBOUND, PRODUCED AN AVERAGE 23.3% WEIGHT LOSS OVER AROUND 11 MONTHS.
THAT COMPARES WITH 14.8% FOR ZEPBOUND ALONE IN PATIENTS WITH TYPE 2 DIABETES.
⚠️ HOWEVER, 11%–27% OF PATIENTS STOPPED THE COMBINATION DUE TO SIDE EFFECTS, KEEPING TOLERABILITY AS AN IMPORTANT CONSIDERATION.
LILLY EXPECTS TO MOVE ELORALINTIDE INTO LATE-STAGE TRIALS LATER THIS YEAR.
#DailyOrbit
Aviso legal: o conteúdo do OKX Orbit é fornecido apenas para fins informativos. Saiba mais
Respostas
Ainda não há comentários. Seja a primeira pessoa a responder!
Criptos em alta
BTC/USDTBitcoin
$84.285,9+0,00%
ETH/USDTEthereum
$2.717,37+0,01%
ZEC/USDTZcash
$1.435,99-0,01%
Destaques do mercado hoje
1#RateHikeDelayedJobsNext
Popular
2#BTCInflowETHOutflow
3#USTreasuryYieldsClimb